Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,206 | 163 | 1,019 |
| Samples | 259 | 50 | 203 |
| Peptides | 210 | 35 | 181 |
Function
CEACAM1 · CEA cell adhesion molecule 1
This gene encodes a member of the carcinoembryonic antigen (CEA) gene family, which belongs to the immunoglobulin superfamily. Two subgroups of the CEA family, the CEA cell adhesion molecules and the pregnancy-specific glycoproteins, are located within a 1.2 Mb cluster on the long arm of chromosome 19. Eleven pseudogenes of the CEA cell adhesion molecule subgroup are also found in the cluster. The encoded protein was originally described in bile ducts of liver as biliary glycoprotein. Subsequently, it was found to be a cell-cell adhesion molecule detected on leukocytes, epithelia, and endothelia. The encoded protein mediates cell adhesion via homophilic as well as heterophilic binding to other proteins of the subgroup. Multiple cellular activities have been attributed to the encoded protein, including roles in the differentiation and arrangement of tissue three-dimensional structure, angiogenesis, apoptosis, tumor suppression, metastasis, and the modulation of innate and adaptive immune responses. Multiple transcript variants encoding different isoforms have been reported, but the full-length nature of all variants has not been defined. [provided by RefSeq, May 2010].
Isoforms & Proteins
6 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 184 amino-acid changes on canonical ENST00000161559 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CEACAM1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CEACAM1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Thymic Epithelial Tumor | 0/0 0% | 2/39 5% |
| Endometrial Carcinoma | 5/42 12% | 14/612 2% |
| Germ Cell Tumour | 2/25 8% | 2/169 1% |
| Other Solid Cancers | 2/94 2% | 20/1515 1% |
| Non-Small Cell Lung Carcinoma | 7/304 2% | 15/1390 1% |
| Melanoma | 2/210 1% | 24/1899 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Esophageal Carcinoma | 0/23 0% | 8/769 1% |
| Gastric Carcinoma | 3/74 4% | 16/1809 1% |
| Rhabdomyosarcoma | 0/33 0% | 2/171 1% |
| Colorectal Carcinoma | 9/143 6% | 21/3239 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 21/2550 1% |
| Ovarian Carcinoma | 2/109 2% | 5/998 0% |
| Other Sarcomas | 2/69 3% | 2/699 0% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Glioma | 0/52 0% | 8/2127 0% |
| Head and Neck Carcinoma | 3/85 4% | 3/1574 0% |
| Hepatocellular Carcinoma | 0/46 0% | 8/2210 0% |
| Non-Cancerous | 1/104 1% | 2/830 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 1/810 0% |
| Breast Carcinoma | 0/144 0% | 8/3264 0% |
| Neuroblastoma | 2/87 2% | 1/1331 0% |
| Bladder Carcinoma | 0/58 0% | 2/956 0% |
| Prostate Carcinoma | 0/13 0% | 4/2105 0% |
| Pancreatic Carcinoma | 0/89 0% | 3/1611 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 1/1592 0% |
Mutation Distribution
Where CEACAM1 is mutated · all tissues, split by cell line vs tissue
How many mutations in CEACAM1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,206 mutations in CEACAM1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|